Fluorodeoxyglucose

Fluorodeoxyglucose enters cells through glucose transporters and is then phosphorylated by hexokinase. Because it undergoes limited further metabolism, the phosphorylated tracer remains relatively localized, allowing its accumulation to reflect cellular glucose use. This biochemical trapping creates differences in signal that PET can map across tissues.

Because uptake reflects glucose use, metabolically active inflammatory and infectious tissues can also accumulate the tracer. Consequently, a region of increased signal is interpreted in clinical context rather than treated as automatically malignant. This broader metabolic basis explains why the same imaging approach contributes to cancer evaluation and to selected inflammatory or infectious conditions.

Fluorine-18 supplies the radioactive signal that makes the examination measurable: its positron emissions are detected by PET and converted into a map of tracer distribution. The resulting image represents metabolic activity across tissues, so clinicians can compare metabolic patterns with anatomical findings when evaluating disease.

It adds information about tissue function that anatomy alone may not show. Areas with differing glucose use can produce contrasting metabolic patterns, helping clinicians assess disease-related activity alongside structural findings. This combined perspective is relevant to detection and evaluation because fluorodeoxyglucose PET can reveal metabolic abnormalities that complement, rather than replace, anatomical imaging.

In oncology, clinicians use the examination for several distinct decisions: detecting suspected disease, determining its extent during staging, assessing response after treatment, and evaluating possible recurrence. These uses rely on metabolic maps to identify and compare active tissue, giving cancer management information beyond a single initial detection study.

Its clinical role extends beyond oncology to inflammatory and infectious conditions, as well as selected neurological and cardiac conditions. In these settings, the examination provides a map of tissue glucose use that may help characterize abnormal activity. The appropriate interpretation depends on the condition being investigated and the metabolic pattern observed.